{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:23:46Z","timestamp":1779186226965,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.beem.2020.101376","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:14:27Z","timestamp":1580429667000},"page":"101376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["What is the role of medical therapy in adrenal-dependent Cushing's syndrome?"],"prefix":"10.1016","volume":"34","author":[{"given":"Leah T.","family":"Braun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9522","key":"10.1016\/j.beem.2020.101376_bib1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing's syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet (London, England)"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2020.101376_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000314297","article-title":"Epidemiology of Cushing's syndrome","volume":"92","author":"Steffensen","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2020.101376_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000443861","article-title":"Cushing's syndrome: where and how to find it","volume":"46","author":"Debono","year":"2016","journal-title":"Front Horm Res"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ecl.2018.01.004","article-title":"Adrenal surgery for cushing's syndrome: an update","volume":"47","author":"Di Dalmazi","year":"2018","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"6","key":"10.1016\/j.beem.2020.101376_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.beem.2020.101376_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-17-0997","article-title":"Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN","volume":"178","author":"Valassi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrendo.2016.24","article-title":"A\u00a0genetic and molecular update on adrenocortical causes of Cushing syndrome","volume":"12","author":"Lodish","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2020.101376_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220154","article-title":"Primary bilateral adrenal nodular disease with Cushing's syndrome: varying aetiology","volume":"2017","author":"Jarial","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.beem.2020.101376_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/cen.12763","article-title":"An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience","volume":"82","author":"Albiger","year":"2015","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib10","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology clinical practice guideline in collaboration with the European Network for the study of adrenal tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2020.101376_bib11","doi-asserted-by":"crossref","first-page":"M61","DOI":"10.1530\/EJE-15-0272","article-title":"Subclinical hypercortisolism: a state, a syndrome, or a disease?","volume":"173","author":"Di Dalmazi","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2020.101376_bib12","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1210\/jc.2014-1401","article-title":"Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing's syndrome: a systematic review of the literature","volume":"99","author":"Di Dalmazi","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2020.101376_bib13","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1007\/s00464-010-1000-7","article-title":"Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation","volume":"24","author":"Guerrieri","year":"2010","journal-title":"Surg Endosc"},{"issue":"9","key":"10.1016\/j.beem.2020.101376_bib14","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1210\/jc.2017-00823","article-title":"Resetting the abnormal Circadian cortisol rhythm in adrenal incidentaloma patients with mild autonomous cortisol secretion","volume":"102","author":"Debono","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17460441.2019.1559146","article-title":"Drug design strategies for Cushing's syndrome","volume":"14","author":"Usanov","year":"2019","journal-title":"Expet Opin Drug Discov"},{"issue":"14","key":"10.1016\/j.beem.2020.101376_bib16","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1517\/14656566.9.14.2423","article-title":"Advances in the medical management of Cushing's syndrome","volume":"9","author":"Pecori Giraldi","year":"2008","journal-title":"Expet Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cen.13414","article-title":"A\u00a0polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome","volume":"87","author":"Valassi","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2020.101376_bib18","first-page":"127","article-title":"Ketoconazole: a new treatment of Cushing syndrome","volume":"87","author":"Leal-Cerro","year":"1986","journal-title":"Med Cl\u00ednica"},{"issue":"12","key":"10.1016\/j.beem.2020.101376_bib19","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/archinte.1982.00340250097015","article-title":"Ketoconazole blocks testosterone synthesis","volume":"142","author":"Pont","year":"1982","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2020.101376_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of cushing's disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.beem.2020.101376_bib21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing's syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"The Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.beem.2020.101376_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-198814010-00002","article-title":"Clinical pharmacokinetics of ketoconazole","volume":"14","author":"Daneshmend","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.beem.2020.101376_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3389\/fendo.2017.00375","article-title":"Multiple salivary cortisol measurements are a useful tool to optimize metyrapone treatment in patients with cushing's syndromes treatment: case presentations","volume":"8","author":"Yoshida","year":"2017","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib25","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1097\/MJT.0000000000000549","article-title":"Preoperative ketoconazole therapy for primary bilateral adrenocorticotropic hormone-independent macronodular adrenal hyperplasia syndrome","volume":"24","author":"Parthvi","year":"2017","journal-title":"Am J Therapeut"},{"issue":"Pt 6","key":"10.1016\/j.beem.2020.101376_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1258\/acb.2010.010167","article-title":"Cortisol measurement in patients receiving metyrapone therapy","volume":"47","author":"Owen","year":"2010","journal-title":"Ann Clin Biochem"},{"issue":"6081","key":"10.1016\/j.beem.2020.101376_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmj.2.6081.215","article-title":"Metyrapone in long-term management of Cushing's disease","volume":"2","author":"Jeffcoate","year":"1977","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.beem.2020.101376_bib28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1507\/endocrj.48.665","article-title":"Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH)","volume":"48","author":"Omori","year":"2001","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.beem.2020.101376_bib29","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating cushing's syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2020.101376_bib31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","article-title":"Metyrapone treatment in Cushing's syndrome: a real-life study","volume":"62","author":"Ceccato","year":"2018","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.beem.2020.101376_bib32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1530\/EC-18-0400","article-title":"Preoperative treatment with metyrapone in patients with cushing's syndrome due to adrenal adenoma","volume":"7","author":"Puglisi","year":"2018","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.beem.2020.101376_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14728214.2015.1047762","article-title":"Emerging drugs for Cushing's disease","volume":"20","author":"Guelho","year":"2015","journal-title":"Expet Opin Emerg Drugs"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0274","article-title":"Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review","volume":"167","author":"Preda","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2044.1986.tb13187.x","article-title":"Etomidate and Cushing's syndrome","volume":"41","author":"Costa","year":"1986","journal-title":"Anaesthesia"},{"issue":"8","key":"10.1016\/j.beem.2020.101376_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF01735795","article-title":"Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome","volume":"66","author":"Allolio","year":"1988","journal-title":"Klin Wochenschr"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib37","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","article-title":"Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects","volume":"70","author":"Schulte","year":"1990","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","article-title":"Mifepristone (RU 486) in Cushing's syndrome","volume":"157","author":"Johanssen","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib39","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.4158\/EP11391.CR","article-title":"Successful long-term treatment of Cushing disease with mifepristone (RU486)","volume":"18","author":"Basina","year":"2012","journal-title":"Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"10.1016\/j.beem.2020.101376_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-015-0059-5","article-title":"Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension","volume":"15","author":"Fein","year":"2015","journal-title":"BMC Endocr Disord"},{"issue":"8","key":"10.1016\/j.beem.2020.101376_bib41","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4158\/EP-2019-0047","article-title":"Mifepristone treatment for mild autonomous cortisol secretion due to adrenal adenomas: a pilot study","volume":"25","author":"Belokovskaya","year":"2019","journal-title":"Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2020.101376_bib42","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1210\/jc.2018-02638","article-title":"Mifepristone treatment in four cases of primary bilateral macronodular adrenal hyperplasia (BMAH)","volume":"104","author":"Cohan","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101376_bib43","first-page":"6161348","article-title":"Effects of mifepristone on nonalcoholic fatty liver disease in a patient with a cortisol-secreting adrenal adenoma","volume":"2017","author":"Ragucci","year":"2017","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.beem.2020.101376_bib44","first-page":"8708401","article-title":"Glucocorticoid receptor antagonist administration prevents adrenal gland atrophy in an ACTH-independent cushing's syndrome rat model","volume":"2019","author":"Yasuda","year":"2019","journal-title":"Int J Pediatr Endocrinol"},{"key":"10.1016\/j.beem.2020.101376_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/CMED.S39997","article-title":"No postoperative adrenal insufficiency in a patient with unilateral cortisol-secreting adenomas treated with mifepristone before surgery","volume":"9","author":"Saroka","year":"2016","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/09513590.2017.1290070","article-title":"A\u00a0successful case of pregnancy in a woman with ACTH-independent Cushing's syndrome treated with ketoconazole and metyrapone","volume":"33","author":"Zieleniewski","year":"2017","journal-title":"Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2020.101376_bib47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12020-017-1428-9","article-title":"Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma","volume":"61","author":"Claps","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2020.101376_bib48","series-title":"Adrenal Tumors, Glucocorticoid Regulation and Action San Diego","article-title":"An open-label study to assess the safety and efficacy of levoketoconazole (COR-003) in the treatment of endogenous Cushing's syndrome","author":"Salvatori","year":"2015"},{"key":"10.1016\/j.beem.2020.101376_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","author":"Fleseriu","year":"2019","journal-title":"The Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2020.101376_bib50","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40261-017-0497-0","article-title":"Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of Cytochrome P450 enzymes in healthy adults","volume":"37","author":"Armani","year":"2017","journal-title":"Clin Drug Invest"},{"issue":"4","key":"10.1016\/j.beem.2020.101376_bib53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/cpdd.389","article-title":"Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study","volume":"7","author":"Hunt","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10.1016\/j.beem.2020.101376_bib54","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1021\/acs.jmedchem.7b00162","volume":"60","author":"Hunt","year":"2017","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.beem.2020.101376_bib55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/en.2017-00512","article-title":"Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice","volume":"159","author":"Kroon","year":"2018","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11102-014-0627-0","article-title":"Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers","volume":"18","author":"Fleseriu","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2020.101376_bib57","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1172\/JCI103988","article-title":"Island D, Smith M, Liddle GW. Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11 beta-hydroxylation","volume":"38","author":"Coppage","year":"1959","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.beem.2020.101376_bib58","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1385\/ENDO:18:3:279","article-title":"Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic Cushing's syndrome","volume":"18","author":"Stiefel","year":"2002","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.beem.2020.101376_bib59","first-page":"25","article-title":"Ketoconazole in the control of arterial hypertension in Cushing's syndrome","volume":"199","author":"Calvo Romero","year":"1999","journal-title":"Rev Cl\u00ednica Espa\u00f1ola"},{"issue":"1","key":"10.1016\/j.beem.2020.101376_bib60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0248-8663(05)82527-5","article-title":"Value of ketoconazole in the treatment of Cushing disease","volume":"14","author":"Pascal","year":"1993","journal-title":"Rev Med Interne"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-92-5-613","article-title":"Sustained remission of Cushing's disease with mitotane and pituitary irradiation","volume":"92","author":"Schteingart","year":"1980","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2020.101376_bib62","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2020.101376_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11102-011-0314-3","article-title":"Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate","volume":"15","author":"Heyn","year":"2012","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.beem.2020.101376_bib64","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101376_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40842-016-0033-9","article-title":"Update on medical treatment for Cushing's disease","volume":"2","author":"Cuevas-Ramos","year":"2016","journal-title":"Clin Med Endocrinol Diabetes"},{"issue":"11","key":"10.1016\/j.beem.2020.101376_bib66","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14656566.2018.1504021","article-title":"New and emerging drug therapies for Cushing's disease","volume":"19","author":"Stormann","year":"2018","journal-title":"Expet Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.beem.2020.101376_bib67","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.clinthera.2008.05.021","article-title":"Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus","volume":"30","author":"Schwartz","year":"2008","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.beem.2020.101376_bib68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejmech.2017.07.078","article-title":"Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1","volume":"139","author":"Gobbi","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"11","key":"10.1016\/j.beem.2020.101376_bib69","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1021\/acs.jmedchem.5b00407","article-title":"Structure-activity relationships, pharmacokinetics, and in\u00a0vivo activity of CYP11B2 and CYP11B1 inhibitors","volume":"58","author":"Papillon","year":"2015","journal-title":"J\u00a0Med Chem"},{"issue":"13","key":"10.1016\/j.beem.2020.101376_bib70","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1021\/acs.jmedchem.8b00328","article-title":"Discovery of novel pyrazole-based selective aldosterone synthase (CYP11B2) inhibitors: a new template to coordinate the heme-iron Motif of CYP11B2","volume":"61","author":"Sakakibara","year":"2018","journal-title":"J\u00a0Med Chem"},{"issue":"11","key":"10.1016\/j.beem.2020.101376_bib71","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.bmcl.2017.04.021","article-title":"Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension","volume":"27","author":"Hoyt","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.beem.2020.101376_bib72","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bmcl.2017.12.015","article-title":"Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in\u00a0vivo activity","volume":"28","author":"Meyers","year":"2018","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:56Z","timestamp":1761497816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X20300038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1521690X20300038"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2020.101376","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the role of medical therapy in adrenal-dependent Cushing's syndrome?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2020.101376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101376"}}